Girentuximab
Girentuximab (G250) is a chimeric monoclonal antibody that binds carbonic anhydrase IX (CAIX), a cell surface glycoprotein ubiquitously expressed in clear cell renal cell carcinoma (ccRCC) [1].
Product Specifications
CAS Number
[916138-87-9]
Product Name Alternative
G250; cG250
UNSPSC
12352203
Target
Carbonic Anhydrase
Type
Inhibitory Antibodies
Related Pathways
Metabolic Enzyme/Protease
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/girentuximab.html
Purity
99.90
Solubility
H2O
Smiles
[Girentuximab]
Molecular Weight
(144.62 kDa)
References & Citations
[1]Chamie K, et al. Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial. JAMA Oncol. 2017;3 (7) :913-920.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Isoform
CA IX
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
